Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: Do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?

HIV Medicine

Volumn 14, Issue 5, 2013, Pages 321-325

  Fanjul, F ^a   Riveiro Barciela, M ^b   Gonzalez, J ^c   Delgado, E ^a   Murillas, J ^a   Payeras Cifre A ^c   Falco V ^b   Riera, M ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL SON LLÀTZER   (Spain)

Author keywords

Central nervous system penetration effectiveness; CPE; HIV; Progressive multifocal leukoencephalopathy; Protease inhibitors; Survival

Indexed keywords

PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; COHORT ANALYSIS; COORDINATION DISORDER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RATING SCALE; RETROSPECTIVE STUDY; SEIZURE; SPAIN; SURVIVAL; TREATMENT PLANNING; VIRUS LOAD; VISUAL IMPAIRMENT; WALKING DIFFICULTY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; FEMALE; HIV INFECTIONS; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; PROGNOSIS; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RNA, VIRAL; SPAIN; SURVIVAL RATE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84875808537     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12008     Document Type: Article

References (20)

1. d'Arminio Monforte A, Cinque P, Mocroft A etal. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-328.
2. Carson KR, Evens AM, Richey EA etal. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
3. Royal W 3rd, Dupont B, McGuire D etal. Topotecan in the treatment of acquired immunodefi ciency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9: 411-419.
4. Hall CD, Dafni U, Simpson D etal. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodefi ciency virus infection. N Engl J Med 1998; 338: 1345-1351.
5. De Luca A, Ammassari A, Pezzotti P etal. Cidofovir in addition to antiretroviral treatment is not eff ective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22: 1759-1767.
6. Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001; 7: 353-357.
7. Ath A, Venkataramana A, Reich DS, Cortese I, Major EO. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology 2006; 66: 149-150.
8. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009; 66: 255-258.
9. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd. Impact of HAART AND CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS 2009; 23: 1893-1901.
10. Marra CM, Zhao Y, Clifford DB etal. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359-1366.
11. Lanoy E, Guiguet M, Bentata M etal. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 2011; 76: 644-651.
12. th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2008 [Abstract 385].
13. Gasnault J, Costagliola D, Hendel-Chavez H etal. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 2011; 6: e20967.
14. Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4: 59-68.
15. Letendre S, Marquie-Beck J, Capparelli E etal. Validation of the CNS penetration-eff ectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
16. Letendre S, Ellis R, Deutsch R etal. Correlates of Time-to-Loss-of-Viral-Response in CSF and Plasma in the CHARTER Cohort. CROI 2010 Poster 430.
17. Marzocchetti A, Tompkins T, Clifford DB etal. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 2009; 73: 1551-1558.
18. Tassie JM, Gasnault J, Bentata M etal. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 1999; 13: 1881-1887.
19. Vlahakis SR, Bennet S, Whitehead S, Badley AD. HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 2007; 12: 969-977.
20. Merabova N, Kaminski R, Krynska B, Amini S, Khalili K, Darbinyan A. JCV agnoprotein-induced reduction in CXCL5/LIX secretion by oligodendrocytes is associated with activation of apoptotic signaling in neurons. J Cell Physiol 2012; 227: 3119-3127.